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Bone Marrow Acid Phosphatase
in the Evaluation of Patients
with Carcinoma of the Prostate
Ronald Kabler, M D * , Riad Farah, M D * ,
Kenneth Greenawald, M D , PhD**, and Joseph C. Cerny, M D *

R e c e n t studies
have indicated that
elevation of acid phosphatase activity in
bone marrow aspirate may be the earliest
indication of advanced carcinoma of the
prostate (stages C and D). Elevation of bone
m a r r o w acid phosphatase (BMAP) frequently reveals abnormality before other
techniques employed in staging prostatic
carcinoma, such as digital palpation of the
gland, serum acid phosphatase, skeletal
metastatic survey, bone scan and lymphangiography. BMAP, therefore, is an essential part of the workup of all patients with
prostatic carcinoma. Its measurement may
be critical in determiriing the stage.of the
disease and appropriate treatment, eg: radical surgery, radiation therapy or hormonal
manipulation.

Based on experience with 30 men having
clinical stage A and B adenocarcinoma of
the prostate, the authors conclude that elevation of bone marrow acid phosphatase
(BMAP) is a sensitive indicator of the disease
state. BMAP revealed periprostatic or nodal
Involvement
when osseous
metastases
seemed absent. BMAP is considered essential in the evaluation of all patients with
prostatic carcinoma. Patients who have false
negative BMAP (and are not candidates for
radical prostatectomy),
should
undergo
lymphangiography
and bone scan before
radiation therapy or hormonal treatment is
planned.

Materials and methods
Thirty men w i t h c l i n i c a l stage A and
B adenocarcinoma of the prostate were
studied. Their ages ranged from 49 to 75
years. Each patient underwent complete
evaluation including serum acid and alkaline phosphatase, skeletal matastatic survey, bone scan, l y m p h a n g i o g r a p h y and
BMAP determination.

' D i v i s i o n of Urology, Department of Surgery
t Department of Pathology

The technique of lymphangiography and
its interpretation in patients with carcinoma
of the prostate has been reported.^

Address reprint requests to Dr. Kabler at Henry
Ford Hospital, 2799 West Grand Boulevard
Detroit, M l 48202.
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BMAP was obtained by atraumatic aspiration of 5 cc of bone marrow from the posterior iliac crest This site was chosen in
preference to the sternum because of the
known free communication of periprostatic,
pelvic and paravertebral veins with the marrow space of the iliac crest. At the time of
m a r r o w a s p i r a t i o n , a blood sample was
drawn and the specimens delivered immediately to the laboratory. Because of instability of the enzyme, analyses for acid
phosphatase were performed within 30 minutes of their receipt in the laboratory. Acid
phosphatase activity was measured by the
Roy method (thymol phosphaline phosphate), as modified for the Dupont ACA.*
This method has great specificity for prostatic acid phosphatase and minimizes the
contribution of acid phosphatase of marrow
cellular, eg: RBC, platelet, origin. Normal
range for both serum and marrow acid phosphatase by this method is 0-0.7 l.U.

was noted i n l O o f t h e l l patients (91%) only
three of whom had elevation of serum acid
phosphatase. One of the 11 patients with
extraprostatic carcinoma had normal BMAP
and serum acid phosphatase levels. Of four
patients with the neoplasm confined to the
prostate gland, one had deviation of BMAP
and all had normal serum acid phosphatase.
Of the 15 patients in Group II with stage D
carcinoma of the prostate, 13 (87%) had
elevated BMAP (range .80-7.2 l.U.; mean
1.9 I.U.). Four of these also had elevated
serum acid phosphatase. In nine patients,
this study was normal. Both patients with
stage D disease and normal BMAP had
normal serum enzyme levels.
Other staging studies and their diagnostic
accuracy in demonstrating advanced (stage
C and D) disease were lymphangiography
55%, bone scan 55%, plasma acid phosphatase 23% and bone survey 14%.

Results
Discussion

Fifteen patients (Group I), in whom staging
studies failed to demonstrate distant metastases, underwent radical retropubic prostatectomy and lymphadenectomy including
the sacral, obturator, hypograstric, external
iliac and common iliac nodal drainage to the
aortic bifurcation. The remaining 15 patients
(Group II) were found to have stage D disease. Seven of these patients received irradiation therapy to the prostate and its nodal
drainage, and eight underwent treatment by
hormonal manipulation.

The accuracy of BMAP in predicting neoplastic dissemination in patients with carcinoma of the prostate, and its superiority to
other staging techniques routinely used in
this disease, were underscored in this study.
Thus, of 11 patients found to have local and
lymphatic extension atthe time of operation,
10 (91%) had elevated BMAP Three of four
operated patients in whom the carcinoma
was confined to the prostate gland had
normal BMAP (75%) and one patient had
false positive elevation. Similarly, in 15 patients with demonstrated stage D metastatic
disease, BMAP was elevated in 13 (87%).

In 11 of 15 patients in Group I (73%),
neoplasm was found to have extended beyond the confines of the prostatic capsule.
Carcinoma was found in the regional lymphatics in six patients, the periprostatic tissues
in fourand seminal vesicles inone. Elevation
of BMAP (range .90-2.0 I.U.; mean 1.2 l.U.),

As described, other frequently employed
staging studies were less accurate in predicting extent of the carcinoma, with bone scan
and lymphangiography demonstrating met-
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astases in 55% of patients, and elevation of
serum acid phosphatase and abnormal bone
survey indicating advanced disease in 23%
and 14%, respectively. These findings do not
obviate the need for these staging techniques, but suggest they be employed to
corroborate BMAP, define the exact location
of metastases when BMAP iselevated and to
demonstrate, when possible, metastatic carcinomaof the prostate in those rare instances
when BMAP is incorrect.

prostatic, pelvic and paravertebral veins
with the marrow space of the iliac crest
suggests that high concentrations of acid
phosphatase may be delivered to bone marrow for sometime priorto equilibration with
the systemic circulation. Long term followup of this group of patients will ultimately
substantiate or refute this mechanism.

Summary

The exact mechanism for elevation of
BMAP is not clear. Probably one or both of
two mechanisms are responsible for elevation of this enzyme in the bone marrow,
while plasma levels remain normal. First, itis
possible that in those patients with normal
bone survey and scan, and only locally
demonstrated periprostatic tumor extension,
there are in fact microscopic foci of neoplasm in the bone marrow, which will later
become clinically apparent. Second, the
extensive and free communication of peri-

It is concluded that (a) BMAP is the most
sensitive indicator of stage C and D carcinoma of the prostate, (b) BMAP is capable
of indicating periprostatic or nodal involvement in the apparent absence of osseous
metastases, (c) lymphangiography and bone
scan are of especial value in patients with
false negative BMAP, and in planning radiation therapy or hormonal manipulation in
patients who are not candidates for radical
surgery.
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